Skip to main content
Premium Trial:

Request an Annual Quote

Sprout Group VCs Hire GlaxoSmithKline Exec; Galapagos Adds CSO

NEW YORK, May 29 - Venture-capital firm Sprout Group has hired former GlaxoSmithKline chief science and technology officer James Niedel, the company said yesterday.


Niedel will be venture partner for health-care technology investments.


Between 1995 and 2001, Niedel was a board member at Glaxo Wellcome, where he oversaw global R&D, information technology, and product strategy.


The Sprout Group is a venture capital affiliate of Credit Suisse First Boston.



Functional-genomics company Galapagos Genomics said on May 21 that it had hired Robin Brown as chief scientific officer.


Brown will direct the company's R&D, particularly in drug target discovery and validation.


He was previously chief scientific officer at the Belgian firm Devgen, and prior to that was at Glaxo Wellcome.


Galapagos is headquartered in Mechelen, Belgium. It is privately held.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.